Seifert Karin, Matu Sangeeta, Javier Pérez-Victoria F, Castanys Santiago, Gamarro Francisco, Croft Simon L
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Int J Antimicrob Agents. 2003 Oct;22(4):380-7. doi: 10.1016/s0924-8579(03)00125-0.
Leishmania donovani promastigote lines resistant to hexadecylphosphocholine (HePC, miltefosine) at 2.5, 5.0, 10.0, 20.0 and 40.0 microM were developed in vitro by continuous step-wise drug pressure. The 40 microM line was 15 times more resistant to HePC than the wild-type clone and showed cross-resistance to the ether lipid ET-18-OCH3 (edelfosine) but not to the standard anti-leishmanial drugs. Resistance was stable up to 12 weeks in drug-free culture medium. No amplification of specific genes, including the multidrug resistance P-glycoprotein gene, could be detected in the resistant parasites.
通过连续逐步施加药物压力,在体外培养出对十六烷基磷酸胆碱(HePC,米替福新)具有抗性的杜氏利什曼原虫前鞭毛体株系,其抗性浓度分别为2.5、5.0、10.0、20.0和40.0微摩尔。40微摩尔株系对HePC的抗性比野生型克隆高15倍,并且对醚脂ET-18-OCH3(依地福新)表现出交叉抗性,但对标准抗利什曼原虫药物没有交叉抗性。在无药物培养基中,抗性在长达12周的时间内保持稳定。在抗性寄生虫中未检测到特定基因的扩增,包括多药耐药P-糖蛋白基因。